Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 4/20 | 0.73 |
| ▸ | HTR2A | P28223 | 3/20 | 0.73 |
| ▸ | DRD2 | P14416 | 2/20 | 0.73 |
| ▸ | DRD3 | P35462 | 2/20 | 0.73 |
| ▸ | DRD4 | P21917 | 1/20 | 0.73 |
| ▸ | HTR2C | P28335 | 1/20 | 0.73 |
| ▸ | ADRB1 | P08588 | 4/20 | 0.61 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.61 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.61 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.61 |
| ▸ | HTR6 | P50406 | 4/20 | 0.56 |
| ▸ | HTR3E | A5X5Y0 | 2/20 | 0.56 |
| ▸ | HTR3B | O95264 | 2/20 | 0.56 |
| ▸ | HTR3A | P46098 | 2/20 | 0.56 |
| ▸ | HTR3D | Q70Z44 | 2/20 | 0.56 |
| ▸ | HTR3C | Q8WXA8 | 2/20 | 0.56 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.56 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.56 |
| ▸ | HTR7 | P34969 | 3/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28078181 | 1.00 | HTR1A (0.73) | HTR1AHTR2ADRD2DRD3DRD4 | |
| SCHEMBL31561598 | 1.00 | HTR1A (0.73) | HTR1AHTR2ADRD2DRD3DRD4 | |
| Hydrochloric Acid SCHEMBL7927336 | 0.98 | HTR1A (0.71) | HTR1AHTR2ADRD2DRD3DRD4 | |
| Piperazine SCHEMBL28217787 | 0.98 | HTR1A (0.71) | HTR1AHTR2ADRD2DRD3DRD4 | |
| Hydrochloric Acid SCHEMBL7982587 | 0.98 | HTR1A (0.71) | HTR1AHTR2ADRD2DRD3DRD4 | |
| Hydrochloric Acid SCHEMBL7983458 | 0.92 | HTR1A (0.63) | HTR1AHTR2ADRD2DRD3DRD4 | |
| SCHEMBL29432674 | 0.87 | HTR1A (0.58) | HTR1AHTR2ADRD2DRD3DRD4 | |
| SCHEMBL404338 | 0.87 | HTR1A (0.58) | HTR1AHTR2ADRD2DRD3DRD4 | |
| SCHEMBL3805551 | 0.86 | HTR1A (0.61) | HTR1AHTR2ADRD2DRD3DRD4 | |
| SCHEMBL13563351 | 0.86 | HTR1A (0.69) | HTR1AHTR2ADRD2DRD3DRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 406 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108017659-A | Benzimidazole and thiazole carboxamides class compound and its application | 沈阳药科大学 | 2018-05-11 | — | — | CN | claimed |
| CN-104046246-B | The chemical-mechanical planarization of tungsten-containing substrate | 气体产品与化学公司 | 2016-06-15 | — | — | CN | claimed |
| US-20140273458-A1 | Chemical Mechanical Planarization for Tungsten-Containing Substrates | AIR PRODUCTS AND CHEMICALS, INC. (US) | 2014-09-18 | — | — | US | claimed |
| EP-2779217-A2 | Chemical mechanical planarization for tungsten-containing substrates | AIR PRODUCTS AND CHEMICALS, INC. (US) | 2014-09-17 | — | — | EP | claimed |
| CN-104046246-A | Chemical Mechanical Planarization for Tungsten-Containing Substrates | AIR PROD & CHEM | 2014-09-17 | — | — | CN | claimed |
| US-20260092134-A1 | Bioreducible Poly (Beta-Amino Ester)s For siRNA Delivery | UNIV JOHNS HOPKINS (US) | 2026-04-02 | — | — | US | disclosed |
| US-12527746-B2 | Peptide/particle delivery systems | THE JOHNS HOPKINS UNIVERSITY (US) | 2026-01-20 | — | — | US | disclosed |
| EP-4642434-A2 | LIPID COMPOSITIONS ON THE BASIS OF IONIZABLE LIPIDS, USE FOR DELIVERY TO IMMUNE CELLS | Life Technologies Corporation (US) | 2025-11-05 | — | — | EP | disclosed |
| US-12458700-B2 | Amine-containing transfection reagents and methods for making and using same | Life Technologies Corporation (US) | 2025-11-04 | — | — | US | disclosed |
| US-12371522-B2 | Bioreducible poly (beta-amino ester)s for siRNA delivery | THE JOHNS HOPKINS UNIVERSITY (US) | 2025-07-29 | — | — | US | disclosed |
| US-20240263196-A1 | Lipid Compositions and Methods for Delivery to Immune Cells | Life Technologies Corporation | 2024-08-08 | — | — | US | disclosed |
| US-12049530-B2 | Multicomponent degradable cationic polymers | THE JOHNS HOPKINS UNIVERISTY (US) | 2024-07-30 | — | — | US | disclosed |
| EP-0313974-A1 | N-substituted derivatives of 1-desoxynojirimycine and 1-desoxymannonojirimycine, process for their preparation and their use as pharmaceuticals | BAYER AG (DE) | 1989-05-03 | — | — | EP | disclosed |
| US-4370330-A | Method of enhancing circulation with piperazines | MERZ & COMPANY (DE) | 1983-01-25 | — | — | US | disclosed |
| US-4370329-A | Piperazine derivatives as circulation-enhancing substances | MERZ & COMPANY (DE) | 1983-01-25 | — | — | US | disclosed |
| US-4213985-A | ANTIULCER AND ATNISECRETORY AGENTS | BOEHRINGER INGELHEIM GMBH (DE) | 1980-07-22 | — | — | US | disclosed |
| US-4147869-A | ADRENERGIC BLOCKING AGENTS FOR TREATMENT OF ANGINA PECTORIS, ARRHYTHMIA AND HYPERTENSION | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1979-04-03 | — | — | US | disclosed |
| US-3992537-A | CNS DEPRESSANTS, NEUROLEPTICS, ANTICHOLESTEREMICS | BOEHRINGER INGELHEIM GMBH (DT) | 1976-11-16 | — | — | US | disclosed |
| US-3948898-A | HYPOTENSIVES, SEDATIVES, ANTIARRHYTHMICS, BRADYCARDIACS | BOEHRINGER INGELHEIM GMBH (DT) | 1976-04-06 | — | — | US | disclosed |
| US-3937708-A | CNS-DEPRESSANTS, NEUROLEPTICS, ANALGESICS, ANTIPHLOGISTICS, SPASMOLYTICS, BRONCHOLYTICS, HYPOTENSIVES, ANTICHOLESTEREMICS | BOEHRINGER INGELHEIM GMBH (DT) | 1976-02-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12527746-B2 | Peptide/particle delivery systems | VEGFA, IGF2BP2, MSTN | HTR1A 1346/4885HTR2A 2114/4885DRD2 3711/4885 |
| US-12458700-B2 | Amine-containing transfection reagents and methods for making and using same | SNRPA, NUDT21, SOAT2 | HTR1A 2495/4885HTR2A 1697/4885DRD2 2537/4885 |
| US-12371522-B2 | Bioreducible poly (beta-amino ester)s for siRNA delivery | AARS1, SLC43A1, PHAX | HTR1A 4516/4885HTR2A 4190/4885DRD2 4287/4885 |
| US-12049530-B2 | Multicomponent degradable cationic polymers | PEF1, FIBP, PARN | HTR1A 2004/4885HTR2A 1473/4885DRD2 2399/4885 |
| US-20260092134-A1 | Bioreducible Poly (Beta-Amino Ester)s For siRNA Delivery | SLC43A1, SLC7A5, SLC7A1 | HTR1A 4712/4885HTR2A 4812/4885DRD2 4774/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.